Search research articles
Contact Us
Filters
Showing results (941-950 of 1,119) with videos related to
Page
of 112
Sort By:
Journal of the American College of Cardiology
|
August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial
Connie N Hess, Stefan James, Renato D Lopes, et al.
Clinical Chemistry
|
May 19, 2017
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome
Mark Y Chan, Megan L Neely, Matthew T Roe, et al.
Blood
|
May 29, 2026
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71
Andre Maurice Small, Siddharth M Patel, Robert P Giugliano, et al.
European Heart Journal
|
December 18, 2021
Alirocumab after acute coronary syndrome in patients with a history of heart failure
Harvey D White, Gregory G Schwartz, Michael Szarek, et al.
JAMA
|
June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry
Kim A Eagle, Michael J Lim, Omar H Dabbous, et al.
The American Journal of Cardiology
|
August 18, 2018
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)
Mali D Worme, Mary K Tan, David W J Armstrong, et al.
International Journal of Cardiology
|
November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
Kenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
Circulation. Cardiovascular Quality and Outcomes
|
November 12, 2019
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Michael Szarek, Ph Gabriel Steg, Dina DiCenso, et al.
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
Journal of Human Hypertension
|
June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial
T I Chang, S Abdalla, G M London, et al.
Page
of 112
Search research articles
Search
Showing results (941-950 of 1,119) with videos related to
Sort By:
Page
of 112
Journal of the American College of Cardiology
|
August 14, 2015
Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial
Connie N Hess, Stefan James, Renato D Lopes, et al.
Clinical Chemistry
|
May 19, 2017
Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome
Mark Y Chan, Megan L Neely, Matthew T Roe, et al.
Blood
|
May 29, 2026
Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71
Andre Maurice Small, Siddharth M Patel, Robert P Giugliano, et al.
European Heart Journal
|
December 18, 2021
Alirocumab after acute coronary syndrome in patients with a history of heart failure
Harvey D White, Gregory G Schwartz, Michael Szarek, et al.
JAMA
|
June 10, 2004
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry
Kim A Eagle, Michael J Lim, Omar H Dabbous, et al.
The American Journal of Cardiology
|
August 18, 2018
Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)
Mali D Worme, Mary K Tan, David W J Armstrong, et al.
International Journal of Cardiology
|
November 18, 2008
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial
Kenneth W Mahaffey, Simon T Tonev, Sarah A Spinler, et al.
Circulation. Cardiovascular Quality and Outcomes
|
November 12, 2019
Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial
Michael Szarek, Ph Gabriel Steg, Dina DiCenso, et al.
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
Journal of Human Hypertension
|
June 5, 2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial
T I Chang, S Abdalla, G M London, et al.
Page
of 112